What Has Been The Evolution of the Drug Eluting Stent Market in Recent Years?
The drug eluting stent market has seen considerable growth due to a variety of factors.
• The drug-eluting stent market has seen strong growth in recent years. It is expected to increase from $7.63 billion in 2024 to $8.29 billion in 2025, with a CAGR of 8.6%.
The market’s growth is attributed to the need for better treatment options, supporting clinical evidence, regulatory approvals, healthcare economics, and evolving guidelines.
How Will the Drug Eluting Stent Market?
The drug eluting stent market is expected to maintain its strong growth trajectory in upcoming years.
• The drug-eluting stent market is expected to grow to $11.37 billion by 2029, with a CAGR of 8.2%.
This growth is driven by an aging population, the expansion of medical indications, favorable healthcare policies, global market expansion, and patient-centered care. Trends include personalized medicine, minimally invasive techniques, emerging healthcare technologies, and next-generation drug formulations.
Which Factors Are Boosting Growth In The Drug Eluting Stent Market?
The increasing prevalence of coronary heart disease is expected to drive the growth of the drug-eluting stent market. Coronary heart disease (CHD) occurs when the coronary arteries become blocked or narrowed due to plaque buildup, leading to severe complications like heart attacks or chest pain. CHD is on the rise due to factors such as sedentary lifestyles, poor diets, aging populations, and increased awareness. Drug-eluting stents (DES) help by reopening narrowed arteries and releasing medication to prevent re-narrowing (restenosis). For example, in May 2024, the Centers for Disease Control and Prevention reported that the percentage of adults aged 18 and over with CHD increased from 4.6% in 2020 to 4.9% in 2022, which is expected to drive the drug-eluting stent market.
What Key Areas Define The Segmentation Of The Global Drug Eluting Stent Market?
The drug eluting stent market covered in this report is segmented –
1) By Product: Polymer-Based, Polymer-Free
2) By Drug: Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs
3) By Scaffold: Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds
4) By Application: Coronary Diseases, Peripheral Vascular Diseases
5) By End-User: Hospitals, Specialty Clinic
Subsegments:
1) By Polymer-Based: Durable Polymer Drug-Eluting Stents, Biodegradable Polymer Drug-Eluting Stents
2) By Polymer-Free: Bare-Metal Stents With Drug Coating, Other Polymer-Free Drug-Eluting Stents
Pre-Book The Drug Eluting Stent Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Drug Eluting Stent Industry?
Companies in the drug-eluting stent market are focusing on enhancing delivery systems like the dual-layer balloon to improve patient outcomes. This system improves the accuracy of drug delivery and stent deployment, ensuring even drug distribution along the arterial wall. Medtronic Plc launched Onyx Frontier in August 2022, a new generation of drug-eluting coronary stents that builds on the performance and data of its predecessor, Resolute Onyx DES. Onyx Frontier DES offers advancements such as a dual-layer balloon, a smaller crossing profile, and better catheter flexibility, boosting deliverability by 16% compared to the earlier model, all while maintaining radial strength.
Who Are the Key Players In The Drug Eluting Stent Market?
Major companies operating in the drug eluting stent market are:
• Johnson & Johnson Services Inc.
• Abbott
• Medtronic plc
• Boston Scientific Corporation
• Terumo Corporation
• InspireMD Inc.
• B. Braun Melsungen AG
• Cook Group Incorporated
• Lepu Medical Technology (Beijing) Co. Ltd.
• Biotronik
• Meril Life Sciences Pvt. Ltd.
• MicroPort Scientific Corporation
• Biosensors International Group Ltd.
• OrbusNeich Medical Company Limited
• Alvimedica Medical Technologies
• Hexacath
• Elixir Medical Corporation
• Translumina GmbH
• Cardionovum GmbH
• QualiMed Innovative Medizinprodukte GmbH
• InSitu Technologies Inc.
• Acrostak AG
• SINOMED Innovation Inc.
• Svelte Medical Systems Inc.
What Is The Most Dominant Region In The Drug Eluting Stent Market?
North America was the largest region in the drug-eluting stent market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
